Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

HCW11-040 is a first-in-class pembrolizumab-based, tetra-valent immune checkpoint inhibitor designated as Company’s franchise ...

The solution to the housing affordability crisis is not to make mortgages cheaper, but to lower housing prices with increased supply.

It's difficult to put an exact price tag on how much index funds have saved investors since their creation in 1975. But it's ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.

Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of ...

HCW Biologics debuted the results from its preclinical study of HCW11-018b, the Company’s lead T-cell engager product candidate, that highlights the uniqueness and advantages of its second-generation ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

Q3 2025 Earnings Call Transcript November 10, 2025 Pagaya Technologies Ltd. misses on earnings expectations. Reported EPS is ...

We were the first in Europe to develop chemotherapeutic agents. We discovered, and with The Royal Marsden developed, the chemotherapy drugs busulfan, chlorambucil, melphalan and carboplatin, which are ...

A college junior in Shanghai used a “universal key” to shut down elevator ad screens to protest their intrusive noise, going ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing ...